Successful Management of Decitabine prior to Full-Dose Idarubicin and Cytarabine in the Treatment of Refractory/Recurrent Acute Myeloid Leukemia

Publisher： Karger

E-ISSN： 1421-9662|137|4|195-200

ISSN： 0001-5792

Source： Acta Haematologica, Vol.137, Iss.4, 2017-04, pp. : 195-200

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Final results of a phase 2 trial of clofarabine and low‐dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia

By  

CANCER, Vol. 121, Iss. 14, 2015-07 ,pp. : 2375-2382

John Wiley & Sons Inc

Access to resources Recommend Favorite

Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and high‐risk myelodysplastic syndrome

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 6, 2015-06 ,pp. : 483-486

John Wiley & Sons Inc

Access to resources Recommend Favorite

G‐CSF Priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 4, 2015-04 ,pp. : 295-300

John Wiley & Sons Inc

Access to resources Recommend Favorite

Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia

By  

CANCER, Vol. 124, Iss. 2, 2018-01 ,pp. : 325-334

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Combination of Fludarabine, Cytarabine and Etoposide Is an Active and Well-Tolerated Regimen in Relapsed/Refractory Acute Myeloid Leukemia

By  

Acta Haematologica, Vol. 131, Iss. 4, 2013-11 ,pp. : 202-207

Karger

Access to resources Recommend Favorite